• Click to edit Master text styles – Second level • Third level – Fourth level » Fifth level Click to edit Master title style Introducing PADciclo™ - because tolerability matters Ophthalmology Innovation Summit, October 16 th 2014 PAD™ Technology releasing the full poten1al of API’s 2014
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
• Click to edit Master text styles – Second level
• Third level – Fourth level
» Fifth level
Click to edit Master title style
Introducing PADciclo™ - because tolerability matters
Ophthalmology Innovation Summit, October 16th 2014
PAD™ Technology -‐ releasing the full poten1al of API’s
2014
• Click to edit Master text styles – Second level
• Third level – Fourth level
» Fifth level
Click to edit Master title style MC2 Biotek Group at a glance § Privately held Danish company
§ Major investor is family behind Danfoss Group (USD 6 bn) § Long term commitment – flexible collabora1on models
§ PAD™ Technology – releasing full poten;al of API’s § Key to a successful drug is a label recognized by payers and clinicians as clinically superior
§ Focus: Clinically superior PAD™ versions of high-‐value marketed topical drugs § PADciclo™ Dry eye (phase II star1ng up) § PADcombo™ Psoriasis (phase II ongoing) § Atopic derma11s (phase I, Q1 2015) § Other PAD™ topical projects in pre-‐clinical development
§ Operates through a network based business model § Company loca1ons in Copenhagen and London § Project teams of highly reputed experts in the US and EU § Strategic collabora1ons with academia and hospitals
• Click to edit Master text styles – Second level
• Third level – Fourth level
» Fifth level
Click to edit Master title style PADciclo™- need for 2nd generation CsA eye drop Ra;onale Challenge Solu;on by PADciclo™
Restasis® is twice daily, it s1ngs and has sub-‐op1mal label – yet a blockbuster
Once daily dosing § CsA penetra1on ~4 fold be]er than Restasis®
Get best in class claim for “treatment” § Novel clinical strategy
• Click to edit Master text styles – Second level
• Third level – Fourth level
» Fifth level
Click to edit Master title style PAD™ droplets are robust with low level of surfactants
• Click to edit Master text styles – Second level
• Third level – Fourth level
» Fifth level
Click to edit Master title style
>1,000 patients treated with PADciclo™ 0.06% in the UK
Collabora;on with Moorfields Pharmaceu;cals (Moorfields Eye Hospital) § Available in the UK since April 2012 as a 0.06% preserva1ve free unlicensed Special § Repeated sales to >300 hospitals, clinics, wholesalers and pharmacies § More than 1,000 pa1ents have been treated
• Click to edit Master text styles – Second level
• Third level – Fourth level
» Fifth level
Click to edit Master title style
MEH analysis of 129 patient files is very encouraging
Safety: § PADciclo™ 0.06% is safe § No decrease in visual acuity, no effect on intraocular pressure and no vital signs
Efficacy: § Qualita1ve data reported by pa1ents and ophthalmologists show improvement of clinical
Click to edit Master title style PADciclo™ is well tolerated and increases ocular delivery
Ocular PK data support once daily ins;lla;on at strengths of 0.03% and 0.06% w/w CsA § PK studies in rabbits show superior ocular
exposure of PADciclo™ compared to Restasis®
§ PADciclo™ once daily is sufficient for saturated delivery to cornea and conjunc1va
0
1
2
3
4
5
6
PADciclo 0.06%, 1x
PADciclo 0.06%, 2x
PADciclo 0.1%, 1x
PADciclo 0.1%, 2x
0.05% Restasis
Fold Exposure over Restasis (AU
C 0-‐24h) Cornea
Conjunc1va
Ocular Exposure rela;ve to Restasis®
PADciclo is safe and very well tolerated up to 6 months § Rabbit safety and tolerability studies conducted at 0.1% strength with 2-‐4 1mes daily dosing § No treatment or administra1on-‐related effects § Systemic exposure of ciclosporin is very low
• Click to edit Master text styles – Second level
• Third level – Fourth level
» Fifth level
Click to edit Master title style
Large PADciclo™ phase II trial is starting up PADciclo™ has the required poten;al
§ Excellent pre-‐clinical data
§ Large scale manufacture in unit dose secured
§ Once daily dosing and high tolerability are key for pa1ent compliance
§ Experience from >1,000 pa1ents in the UK and 129 pa1ent files
§ Outcome of Scien1fic Advice mee1ngs support our clinical strategy
Fast to market and best in class
• Click to edit Master text styles – Second level
• Third level – Fourth level
» Fifth level
Click to edit Master title style
Opportuni;es using PAD™ vehicle: § Reformulate high value marketed drugs + LCM § Release the full poten1al of API’s from first formula1on
PAD™ Technology - release the full potential of API’s
§ The right vehicle can provide the twist that makes a superior product
§ PAD™ Technology does not impose addi1onal risk -‐ only pharmacopeial excipients
§ Key differen1a1ng features of the PAD™ Technology:
Penetra1on Solubility Stability
Compliance Tolerability Patented
• Click to edit Master text styles – Second level
• Third level – Fourth level
» Fifth level
Click to edit Master title style We welcome collaboration